Table 1 Clinical data of all stage III patients
Total | pN1 | pN2 | p value | LNR low | LNR high | p value | |
|---|---|---|---|---|---|---|---|
n = 58a (100%) | n = 38a (65.5%) | n = 20a (34.5%) | n = 26a (44.8%) | n = 32a (55.2%) | |||
Ageb (years) | 71 (65–78) | 71 (63–77) | 73 (65–80) | 0.330 | 66 (56–77) | 72 (67–79) | 0.050 |
Gender | |||||||
- Male | 36 (62.1) | 22 (57.9) | 14 (70.0) | 0.408 | 15 (57.7) | 21 (65.6) | 0.594 |
- Female | 22 (37.9) | 16 (42.1) | 6 (30.0) | 11 (42.3) | 11 (34.4) | ||
Localization | |||||||
- Right colon | 24 (41.4) | 16 (42.1) | 8 (40.0) | 0.784 | 11 (42.3) | 13 (40.6) | 0.624 |
- Transverse colon | 1 (1.7) | 1 (2.6) | – | 1 (3.8) | – | ||
- Left colon | 15 (25.9) | 9 (23.7) | 6 (30.0) | 6 (23.1) | 9 (28.1) | ||
- Sigmoid colon | 18 (31.0) | 12 (31.6) | 6 (30.0) | 8 (30.8) | 10 (31.3) | ||
T category | |||||||
- pT1 | 3 (5.2) | 3 (7.9) | – | 0.050 | 1 (3.9) | 2 (6.2) | 0.539 |
- pT2 | 4 (6.9) | 4 (10.5) | – | 3 (11.5) | 1 (3.1) | ||
- pT3 | 42 (72.4) | 28 (73.7) | 14 (70.0) | 19 (73.1) | 23 (71.9) | ||
- pT4 | 9 (15.5) | 3 (7.9) | 6 (30.0) | 3 (11.5) | 6 (18.8) | ||
Tumor grading | |||||||
- G1 | – | – | – | 0.055 | – | – | 0.543 |
- G2 | 44 (75.9) | 32 (84.2) | 12 (60.0) | 21 (80.8) | 23 (71.9) | ||
- G3 | 14 (24.1) | 6 (15.8) | 8 (40.0) | 5 (19.2) | 9 (28.1) | ||
AJCC stage | |||||||
- IIIa | 7 (12.1) | 7 (18.4) | – | < 0.001 | 4 (15.4) | 3 (9.4) | < 0.001 |
- IIIb | 32 (55.2) | 31 (81.6) | 1 (5.0) | 22 (84.6) | 10 (21.2) | ||
- IIIc | 19 (32.7) | – | 19 (95.0) | – | 19 (59.4) | ||
Total number of LN analyzedb | 23 (14–32) | 21 (14–29) | 25 (18–37) | 0.149 | 25 (19–31) | 21 (13–32) | 0.159 |
Patients with adjuvant chemotherapy | 43 (74.1) | 29 (76.3) | 14 (70.0) | 0.753 | 19 (73.1) | 24 (75.0) | 1.000 |
Center | |||||||
- Olten | 33 (56.9) | 18 (47.4) | 15 (75.0) | 0.130 | 15 (57.7) | 18 (56.3) | 0.416 |
- Biel | 15 (25.9) | 12 (31.6) | 3 (15.0) | 5 (19.2) | 10 (31.2) | ||
- Basel | 10 (14.2) | 8 (21.0) | 2 (10.0) | 6 (23.1) | 4 (12.5) | ||